| Primary |
| Prostate Cancer |
28.5% |
| Prostate Cancer Metastatic |
19.3% |
| Product Used For Unknown Indication |
15.7% |
| Hypertension |
5.9% |
| Musculoskeletal Pain |
3.6% |
| Depression |
2.7% |
| Gastrointestinal Disorder Therapy |
2.7% |
| Anxiety |
2.4% |
| Cerebrovascular Accident |
2.4% |
| Gout |
2.1% |
| Hypercholesterolaemia |
2.1% |
| Ill-defined Disorder |
2.1% |
| Neuralgia |
2.1% |
| Pain |
2.1% |
| Transient Ischaemic Attack |
2.1% |
| Metastases To Bone |
1.2% |
| Prophylaxis |
1.2% |
| Oedema |
0.9% |
| Bipolar Disorder |
0.6% |
| Blood Pressure Increased |
0.6% |
|
| Anaemia |
14.9% |
| Cerebral Ischaemia |
6.4% |
| Death |
6.4% |
| Hepatic Function Abnormal |
6.4% |
| Pulmonary Embolism |
6.4% |
| Transaminases Increased |
6.4% |
| Asthenia |
4.3% |
| Drug Ineffective |
4.3% |
| Hyponatraemia |
4.3% |
| Inappropriate Schedule Of Drug Administration |
4.3% |
| Muscular Weakness |
4.3% |
| Nausea |
4.3% |
| Neoplasm Progression |
4.3% |
| Oesophagitis |
4.3% |
| Pulmonary Oedema |
4.3% |
| Sepsis |
4.3% |
| Thrombocytopenia |
4.3% |
| Acute Myocardial Infarction |
2.1% |
| Alanine Aminotransferase Increased |
2.1% |
| Aspartate Aminotransferase Increased |
2.1% |
|
| Secondary |
| Prostate Cancer |
24.5% |
| Product Used For Unknown Indication |
18.5% |
| Prostate Cancer Metastatic |
17.0% |
| Hypertension |
6.1% |
| Pain |
4.2% |
| Musculoskeletal Pain |
3.6% |
| Anxiety |
2.7% |
| Depression |
2.7% |
| Gastrointestinal Disorder Therapy |
2.7% |
| Cerebrovascular Accident |
2.4% |
| Gout |
2.1% |
| Hypercholesterolaemia |
2.1% |
| Ill-defined Disorder |
2.1% |
| Neuralgia |
2.1% |
| Transient Ischaemic Attack |
2.1% |
| Metastases To Bone |
1.2% |
| Prophylaxis |
1.2% |
| Chemotherapy |
0.9% |
| Oedema |
0.9% |
| Analgesic Therapy |
0.6% |
|
| Anaemia |
11.6% |
| Cerebral Ischaemia |
7.0% |
| Crepitations |
7.0% |
| Hepatic Function Abnormal |
7.0% |
| Hypokalaemia |
7.0% |
| Muscular Weakness |
7.0% |
| Drug Ineffective |
4.7% |
| Hyponatraemia |
4.7% |
| Inappropriate Schedule Of Drug Administration |
4.7% |
| Malaise |
4.7% |
| Nausea |
4.7% |
| Oesophagitis |
4.7% |
| Pulmonary Oedema |
4.7% |
| Renal Failure Acute |
4.7% |
| Transaminases Increased |
4.7% |
| Alanine Aminotransferase Increased |
2.3% |
| Asthenia |
2.3% |
| Atrial Fibrillation |
2.3% |
| Bone Pain |
2.3% |
| Cardiac Failure |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
32.6% |
| Prostate Cancer |
21.4% |
| Drug Use For Unknown Indication |
7.9% |
| Prostate Cancer Metastatic |
7.4% |
| Metastases To Bone |
5.6% |
| Pain |
5.1% |
| Constipation |
2.3% |
| Depression |
2.3% |
| Immune Enhancement Therapy |
2.3% |
| Supportive Care |
2.3% |
| Hypertension |
1.9% |
| Nausea |
1.4% |
| Analgesic Therapy |
0.9% |
| Bone Disorder |
0.9% |
| Breakthrough Pain |
0.9% |
| Breast Cancer Metastatic |
0.9% |
| Hormone-refractory Prostate Cancer |
0.9% |
| Insomnia |
0.9% |
| Promotion Of Peripheral Circulation |
0.9% |
| Prophylaxis |
0.9% |
|
| Dyspnoea |
11.1% |
| Osteonecrosis Of Jaw |
11.1% |
| Osteonecrosis |
7.4% |
| Rhabdomyolysis |
7.4% |
| Vomiting |
7.4% |
| Acetabulum Fracture |
3.7% |
| Anaemia |
3.7% |
| Bacterial Infection |
3.7% |
| Blood Parathyroid Hormone Increased |
3.7% |
| Blood Pressure Decreased |
3.7% |
| Cardiac Arrest |
3.7% |
| Colon Cancer Metastatic |
3.7% |
| Fall |
3.7% |
| General Physical Health Deterioration |
3.7% |
| Haemoglobin Abnormal |
3.7% |
| Hormone-refractory Prostate Cancer |
3.7% |
| Hypocalcaemia |
3.7% |
| Hypotension |
3.7% |
| Infection |
3.7% |
| Insomnia |
3.7% |
|
